AI Strategy Assessment - From AI Activity to Strategic Clarity
A 6-week strategic engagement for pharmaceutical, biotech, and healthcare organisations that need to move beyond diagnosis and define the opportunities, priorities, and financial logic required for a credible AI strategy.
When a diagnosis is not enough
Some organisations do not need help confirming that a strategic gap exists. They already know it does. What they need is a more rigorous view of where the opportunity sits, what is getting in the way, which areas matter most, and how to begin building the case for action. That is the role of the Board-Defensible AI Strategy Assessment. It goes beyond diagnosis to evaluate readiness, define priority opportunities, and create a stronger basis for strategic and financial decision-making.
Who this is for
This engagement is designed for organisations that already have AI activity underway and need a deeper strategic evaluation before committing to a full Blueprint.
It is the right fit when:
• AI initiatives exist, but do not add up to a coherent strategy
• leadership needs a clearer view of the highest-value opportunities
• there is pressure to prioritise where AI should create measurable impact
• governance, ownership, privacy, and adoption issues are slowing progress
• the organisation needs stronger strategic and financial logic before committing to a larger programme
This is not a generic maturity review.
It is a focused strategic engagement designed to clarify where the organisation stands and what should happen next.
What the Strategic Assessment is designed to do
Over six weeks, Eularis works with your organisation to assess current AI activity, identify strategic gaps, define priority opportunities, and begin shaping the financial logic required for a board-defensible direction.
The engagement is designed to help leadership answer questions such as:
• Where is AI activity failing to translate into strategic value?
• Which opportunity areas matter most commercially or operationally?
• What governance, ownership, privacy, and adoption barriers need to be addressed?
• Where should the organisation focus first?
• What is the early financial case for those priorities?
What you receive
At the end of the engagement, you will have:
• a strategic assessment of current AI activity and organisational readiness
• identification of key gaps and friction points
• prioritised AI opportunity areas
• early financial modelling to support internal discussion
• a clearer view of what is required to move into a full strategy
For organisations that need a complete strategy, governance design, vendor analysis, due diligence, and implementation pathway, the next step is the AI Strategic Blueprint.
Why this stage matters
The Strategic Assessment is where the conversation starts to move from broad AI ambition to sharper strategic choices.
It gives leadership a stronger basis for deciding:
• where AI should create value first
• which opportunities justify further investment
• what barriers need to be addressed early
• whether the organisation is ready for a full Blueprint
This is often the stage that turns AI from an interesting topic into a credible investment discussion.
What you receive
At the end of the sprint, you will have a clearer view of where you stand and what needs to happen next.
Typical outputs include:
- a strategic diagnosis of current AI activity
- identification of major gaps, risks, and friction points
- a view of where value is being lost or stalled
- prioritised observations on what needs to change
- a recommendation on the most appropriate next step
For some organisations, that next step is a deeper strategic assessment.For others, it is the development of a full AI Strategic Blueprint.
Either way, the sprint gives leadership a more credible basis for decision-making.
Relevant across complex healthcare environments
While Eularis’ primary focus is pharmaceutical and biotech strategy, the same strategic logic also applies in large hospital networks and health systems.
Different environment. Similar challenge.
- Fragmented initiatives.
- Multiple stakeholder groups.
- High governance and privacy requirements.
- Pressure to show measurable value.
- A need for strategic coherence before scale.
That is why this assessment works across complex, regulated healthcare settings.
Why Eularis
Eularis has been building AI strategy in life sciences since 2003.
We combine strategic diagnosis, opportunity definition, and early financial logic in a way that helps leadership move from broad AI ambition to a clearer investment case.
Our work is vendor-neutral and grounded in business reality, governance maturity, and implementation constraints.
How this differs from the Diagnostic Sprint
The Diagnostic Sprint identifies whether a meaningful strategic gap exists and where the main friction sits.
The Strategic Assessment goes further.
It evaluates the organisation in more depth, defines the opportunity space, and begins building the strategic and financial logic needed for larger decisions.
How this differs from the AI Strategic Blueprint
The Strategic Assessment is not the full strategy.
It does not go as far as detailed initiative design, full financial modelling, vendor analysis, due diligence, governance architecture, or implementation planning.
That is the role of the AI Strategic Blueprint.
The Strategic Assessment is the bridge between diagnosis and full strategic design.